Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Matthew Well..
Form 4 Erie Indemnity Company: William David Edwards (Director) For: 31 October
51,307.10 -214.2 -0.42% 7,383.30 +29.5 +0.40% 16.5467 +0.0817 +0.50% 1.114 -0.0079 -0.70% 1.3352 -0.0112 -0.83% 158.50 +0.81 +0.51% 211.61 -0.47 -0.22% 1.4129 +0.0110 +0.78% 0.6868 -0.0063 -0.91% 52,400.00 +1,100 +2.14% 489,771.00 -1,400 -0.29% 75,725.00 -1,987 -2.56% NameLastChg. %Vol.
Form 144 PROCTER & GAMBLE Co For: 8 November
51,307.10 -214.2 -0.42% 7,383.30 +29.5 +0.40% 16.5467 +0.0817 +0.50% 1.114 -0.0079 -0.70% 1.3352 -0.0112 -0.83% 158.50 +0.81 +0.51% 211.61 -0.47 -0.22% 1.4129 +0.0110 +0.78% 0.6868 -0.0063 -0.91% 52,400.00 +1,100 +2.14% 489,771.00 -1,400 -0.29% 75,725.00 -1,987 -2.56% NameLastChg. %Vol.
Form 144 BillionToOne For: 8 November
51,307.10 -214.2 -0.42% 7,383.30 +29.5 +0.40% 16.5467 +0.0817 +0.50% 1.114 -0.0079 -0.70% 1.3352 -0.0112 -0.83% 158.50 +0.81 +0.51% 211.61 -0.47 -0.22% 1.4129 +0.0110 +0.78% 0.6868 -0.0063 -0.91% 52,400.00 +1,100 +2.14% 489,771.00 -1,400 -0.29% 75,725.00 -1,987 -2.56% NameLastChg. %Vol.
Form 4 Aeon Biopharma Inc For: 8 November
51,307.10 -214.2 -0.42% 7,383.30 +29.5 +0.40% 16.5467 +0.0817 +0.50% 1.114 -0.0079 -0.70% 1.3352 -0.0112 -0.83% 158.50 +0.81 +0.51% 211.61 -0.47 -0.22% 1.4129 +0.0110 +0.78% 0.6868 -0.0063 -0.91% 52,400.00 +1,100 +2.14% 489,771.00 -1,400 -0.29% 75,725.00 -1,987 -2.56% NameLastChg. %Vol.
Form 4 STARZ ENTERTAINMENT CORP /CN/: James M. Kapenstein (Officer) For: 2 November
Form 4 STARZ ENTERTAINMENT CORP /CN/: James M. Kapenstein (Officer) For: 2 November Form 4 STARZ ENTERTAINMENT CORP /CN/: James M. Kapenstein (Officer) For: 2 November Form 4 STARZ ENTERTAINMENT CORP /CN/: James M.
Form 4 STARZ ENTERTAINMENT CORP /CN/: Jeffrey Hirsch (Director, President and CEO) For: 2 November
51,307.10 -214.2 -0.42% 7,383.30 +29.5 +0.40% 16.5467 +0.0817 +0.50% 1.114 -0.0079 -0.70% 1.3352 -0.0112 -0.83% 158.50 +0.81 +0.51% 211.61 -0.47 -0.22% 1.4129 +0.0110 +0.78% 0.6868 -0.0063 -0.91% 52,400.00 +1,100 +2.14% 489,771.00 -1,400 -0.29% 75,725.00 -1,987 -2.56% NameLastChg. %Vol.
Form 4 Palantir Technologies Inc For: 8 November
51,307.10 -214.2 -0.42% 7,383.30 +29.5 +0.40% 16.5467 +0.0817 +0.50% 1.114 -0.0079 -0.70% 1.3352 -0.0112 -0.83% 158.50 +0.81 +0.51% 211.61 -0.47 -0.22% 1.4129 +0.0110 +0.78% 0.6868 -0.0063 -0.91% 52,400.00 +1,100 +2.14% 489,771.00 -1,400 -0.29% 75,725.00 -1,987 -2.56% NameLastChg. %Vol.
Form S-3ASR Acadia Realty Trust For: 8 November
51,307.10 -214.2 -0.42% 7,383.30 +29.5 +0.40% 16.5467 +0.0817 +0.50% 1.114 -0.0079 -0.70% 1.3352 -0.0112 -0.83% 158.50 +0.81 +0.51% 211.61 -0.47 -0.22% 1.4129 +0.0110 +0.78% 0.6868 -0.0063 -0.91% 52,400.00 +1,100 +2.14% 489,771.00 -1,400 -0.29% 75,725.00 -1,987 -2.56% NameLastChg. %Vol.
Form 4 Nordson Corporation: Srinivas Subramanian (Executive Vice President) For: 31 October
Form 4 Nordson Corporation: Srinivas Subramanian (Executive Vice President) For: 31 October Form 4 Nordson Corporation: Srinivas Subramanian (Executive Vice President) For: 31 October Form 4 Nordson Corporation: Srinivas Subramanian (Executive Vice President) For: 31 October 51,307.10 -214.2 -0.42% 7,383.30 +29.5 +0.40% 16.5467 +0.0817 +0.50% 1.114 -0.0079 -0.70% 1.3352 -0.0112 -0.83% 158.50 +0.81 +0.51% 211.61 -0.47 -0.22% 1.4129 +0.0110 +0.78% 0.6868 -0.0063 -0.91% 52,400.00 +1,100 +2.14%...
Form 4 Ribbon Communications Inc: Stephen J. McCaffery (EVP, Global Sales) For: 31 October
Form 4 Ribbon Communications Inc: Stephen J. McCaffery (EVP, Global Sales) For: 31 October Form 4 Ribbon Communications Inc: Stephen J. McCaffery (EVP, Global Sales) For: 31 October Form 4 Ribbon Communications Inc: Stephen J.
Form 4 Nordson Corporation: Milton Mayo Morris (Director) For: 1 November
51,307.10 -214.2 -0.42% 7,383.30 +29.5 +0.40% 16.5467 +0.0817 +0.50% 1.114 -0.0079 -0.70% 1.3352 -0.0112 -0.83% 158.50 +0.81 +0.51% 211.61 -0.47 -0.22% 1.4129 +0.0110 +0.78% 0.6868 -0.0063 -0.91% 52,400.00 +1,100 +2.14% 489,771.00 -1,400 -0.29% 75,725.00 -1,987 -2.56% NameLastChg. %Vol.
Cullen/Frost Bankers chief accounting officer Henson sells $85,290 of stock
Matthew Bradley Henson, Chief Accounting Officer at Cullen/Frost Bankers, Inc. (), sold common stock totaling $85,290 on November 2, 2026, according to a recent filing with the Securities and Exchange Commission. The transaction involved the sale of 534 shares of the company’s common stock at a price of $159.72 per share. Following this sale, Mr. Henson directly holds 317 shares of common stock.
Buy the dip in this Canadian stock: RJ
Investing.com -- A sharp selloff in a Canadian lumber producer has created an attractive buying opportunity, with Raymond James arguing that concerns over its exposure to a financially troubled pulp maker are overstated and overlook improving earnings, strong margins and significant longer-term upside. I Raymond James reiterated its Strong Buy rating on Interfor Corp ()after shares plunged 11% on November 6, significantly underperforming a broadly flat Toronto Stock Exchange.
Form 4 Procter & Gamble: Paul Gama (CEO- Health Care) For: 30 October
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Buy this stock for the company’s copper exposure: BofA
51,307.10 -214.2 -0.42% 7,383.30 +29.5 +0.40% 16.5467 +0.0817 +0.50% 1.114 -0.0079 -0.70% 1.3352 -0.0112 -0.83% 158.50 +0.81 +0.51% 211.61 -0.47 -0.22% 1.4129 +0.0110 +0.78% 0.6868 -0.0063 -0.91% 52,400.00 +1,100 +2.14% 489,771.00 -1,400 -0.29% 75,725.00 -1,987 -2.56% NameLastChg. %Vol.
Setup in this Canadian industrial stock is ’attractive’, BMO says
Investing.com -- BMO Capital Markets sees a potential 46% return in a Canadian industrial stock, betting that strong international growth and easing AI-related disruption fears will outweigh a slower-than-expected recovery in the U.S. infrastructure market. The bank maintained its Outperform rating and C$275 price target on WSP Global, implying a potential total return of 46% from its November 5 closing price of C$189.48.
Pacira’s final earnings in spotlight before $1.65B sale
is set to report third-quarter results on Monday, November 9, delivering what could be its final earnings report as a standalone company before completes its $1.65 billion acquisition by year-end. The results will offer investors a last look at whether the pain-management specialist’s business momentum justifies the deal price, even as analysts rate the stock a hold with a mean price target of $33.57, implying 7.8% downside from current levels.
Equity positioning suffered one of its sharpest weekly drops on record: DB
Investing.com - Global equity positioning has plummeted to a massive underweight, registering one of the sharpest weekly declines on record as forced unwinding hammered the technology sector, according to a new research report from Deutsche Bank. The firm’s consolidated measure of equity positioning plunged to the 20th percentile.
U.S. memo alleges Nvidia’s CEO was romantically linked to suspected Beijing spy
Investing.com -U.S. intelligence agencies believe Chief Executive Jensen Huang had a romantic relationship with a Chinese national suspected of being recruited to spy for Beijing, the Financial Times reported on Saturday, citing people familiar with the matter.
UBS raises Dropbox stock price target on margin expansion outlook
Investing.com - UBS raised its price target on Dropbox Inc. () to $26 from $23 while maintaining a Sell rating on the shares. The company reported revenue that beat expectations by one percentage point, declining 1% on a constant currency basis, or flat excluding FormSwift. Dropbox added approximately 60,000 core customers in the quarter, marking another period of positive customer growth.
Visium Technologies director Niclas Adler buys $650,000 in stock
Bo Niclas Adler, a director and 10% owner of VISIUM TECHNOLOGIES, INC. (), acquired a total of $650,000 in company stock and convertible preferred stock on April 3, 2026. The transactions were reported in an amended filing, correcting details from an earlier report. Mr. Adler purchased 500,000,000 shares of common stock at a price of $0.0007 per share, totaling $350,000. Additionally, he acquired 3 shares of Series AA Convertible Preferred Stock for $100,000 per share, amounting to $300,000.
B.Riley cuts Indie Semiconductor stock price target on sector pressure
Investing.com - B.Riley lowered its price target on Indie Semiconductor Inc () to $4.00 from $6.00 while maintaining a Buy rating on the stock. The firm cited recent sector compression as the reason for the adjustment. The stock has struggled significantly, trading at $1.35 near its 52-week low of $1.34, with shares down roughly 71% over the past year.
UBS cuts 10X Genomics stock price target on valuation concerns
Investing.com - UBS lowered its price target on 10X Genomics stock () to $61 from $90 while maintaining a Neutral rating on the shares. The stock currently trades at $58.06, having declined 17% over the past week despite posting a remarkable 347% gain over the last year, according to InvestingPro data. The firm views the company’s third quarter results as largely in line with expectations, with a modest positive skew from strong consumables growth.
UBS raises Liberty Formula One stock price target on F1 profit outlook
Investing.com - UBS raised its price target on Liberty Formula One () to $116 from $110 while maintaining a Neutral rating on the stock. The stock currently trades at $106.52, near its 52-week high of $108.35, and has surged 15% over the past week alone. The company reported total revenues of $1.23 billion and EBITDA of $353 million, compared with Wall Street estimates of $1.24 billion and $362 million. Improved profits at F1 offset lighter MotoGP results and higher corporate losses.
Citi explains why the AI trade may remain under pressure Original
Investing.com -- Citi told clients in a note on Friday that the AI trade could remain under pressure after the U.S. midterm elections, and it prefers European stocks over U.S. equities for now. The bank noted that markets typically pull back ahead of midterms and rally afterward, with its seasonal analysis pointing to November-December returns of 3% to 4%. However, Citi said this year’s pre-election weakness had other causes.
BTIG reiterates Texas Roadhouse stock rating citing sales recovery
Investing.com - BTIG maintained a Buy rating and $220 price target on Texas Roadhouse () following the company’s third quarter results. The restaurant chain reported third quarter results that reflected the impact of a viral hoax video that affected guest traffic in September and October. Despite the near-term headwinds, the company maintains a market capitalization of $12.59 billion and posted revenue growth of 9.89% over the last twelve months.
Needham raises First Advantage stock price target on labor recovery
Investing.com - Needham raised its price target on First Advantage () shares to $30 from $28 while maintaining a Buy rating following the company’s third-quarter results. The background screening company beat Wall Street estimates on revenue and earnings, driven by a broad-based labor market recovery. First Advantage attributed the strength to improved hiring in transportation, retail, and manufacturing verticals, along with strong demand for re-screening and monitoring services.
Raymond James cuts CVS Health stock price target on split valuation
Investing.com - Raymond James lowered its price target on CVS Health () to $103 from $120 while maintaining an Outperform rating. The stock currently trades at $81.33, down nearly 10% over the past week, suggesting potential upside to the analyst’s target. The firm now values the business on a sum-of-the-parts basis following CVS Health’s announcement that it will split off its retail drugstore business from its health insurance, pharmacy benefit management, and specialty pharmacies operations.
Raymond James downgrades ARS Pharmaceuticals stock rating on weak sales
Investing.com - Raymond James downgraded ARS Pharmaceuticals Inc () to Outperform from Strong Buy and lowered its price target to $17.00 from $28.00. The stock currently trades at $2.65, near its 52-week low of $2.59, suggesting substantial upside to the new target. According to InvestingPro analysis, the stock appears undervalued with a Fair Value of $4.41.
Oppenheimer reiterates Serve Robotics stock rating on resilient demand
Investing.com - Oppenheimer reiterated an Outperform rating and $7.00 price target on Serve Robotics (). The stock currently trades at $2.32, near its 52-week low of $2.25, which InvestingPro data suggests is undervalued compared to its Fair Value of $3.31. The firm noted the company delivered upside to third-quarter 2026 revenue and fourth-quarter 2026 guidance as demand for its servers proves resilient outside of its previous relationship with Uber.
K&F Growth Acquisition Corp. II extends business combination deadline after shareholder approval
K&F Growth Acquisition Corp. II (, NASDAQ:KFII, NASDAQ:KFIIR) announced that its shareholders approved an extension to the deadline for completing an initial business combination. The decision was made at an extraordinary general meeting held Wednesday. Shareholders voted to amend the company’s memorandum and articles of association, extending the business combination deadline from November 6, 2026 to August 6, 2027, or an earlier date as determined by the board.
This chip inspection leader fell 24.5% in a month: is the dip worth a look?
Investing.com and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Investing.com — Semiconductor equipment stocks spent October under heavy pressure, as heightened export restrictions and cyclical pauses in foundry capital expenditures dragged the sector down 25% to 35%.
Passage Bio shareholders approve merger with Remix Therapeutics and reverse stock split
Shareholders of Passage Bio, Inc. () approved a series of proposals at a special meeting held Thursday relating to the company’s planned merger with Remix Therapeutics, Inc., according to a press release statement based on the company’s SEC filing. Key measures passed include the issuance of Passage Bio common stock to Remix securityholders, which will represent more than 20% of the outstanding shares and result in a change of control under Nasdaq rules.
Mizuho raises Pulse Biosciences stock price target on trial progress
Investing.com - Mizuho raised its price target on Pulse Biosciences shares () to $65 from $55 while maintaining an Outperform rating. The stock has surged roughly 287% year-to-date, trading at $53.07, though InvestingPro data suggests the shares may be overvalued at current levels. The firm cited several developments from the company’s third quarter of 2026.
Erayak advances generator development, expands manufacturing
WENZHOU, China - Erayak Power Solution Group Inc. () announced progress on manufacturing expansion and product development programs, according to a press release statement issued today. The company’s subsidiary, Ruike Electronics (Wenzhou) Co., Ltd., has entered the final construction acceptance phase for a new manufacturing facility. Erayak expects the acceptance process for all main buildings to be completed in the first quarter of 2027.
Ares Coml RE earnings beat by $0.10, revenue topped estimates
Published Nov 06, 2026, 06:11 AM Ares Coml RE earnings beat by $0.10, revenue topped estimates Ares Coml RE earnings beat by $0.10, revenue topped estimates Investing.com - Ares Coml RE () reported third quarter EPS of $0.12, $0.10 better than the analyst estimate of $0.02. Revenue for the quarter came in at $13.51M versus the consensus estimate of $12.43M. Ares Coml RE’s stock price closed at $3.40. It is down -30.18% in the last 3 months and down -32.81% in the last 12 months.
Humana earnings beat by $0.30, revenue topped estimates
Investing.com - Humana () reported third quarter EPS of $-0.70, $0.30 better than the analyst estimate of $-1.00. Revenue for the quarter came in at $41.16B versus the consensus estimate of $40.87B. Guidance Humana sees FY 2026 EPS of $9.50 versus the analyst consensus of $9.16. Humana’s stock price closed at $411.79. It is up 6.96% in the last 3 months and up 63.38% in the last 12 months. Humana saw 6 positive EPS revisions and 17 negative EPS revisions in the last 90 days.
Starry Sea Acquisition extends merger deadline with $60,000 trust deposit
Starry Sea Acquisition Corp () has extended the deadline to complete its initial business combination by one month, following a $60,000 deposit into its trust account. The company reported the extension in a press release statement filed with the Securities and Exchange Commission. On Monday, Starry Sea Acquisition deposited the funds to move the deadline for its business combination from November 7, 2026, to December 7, 2026.
Oppenheimer reiterates Outperform on HA Sustainable stock, $52 target
Investing.com - Oppenheimer reiterated an Outperform rating and $52.00 price target on HA Sustainable Infrastructure Capital (). The company beat the third-quarter 2026 consensus adjusted earnings per share estimate while reiterating fiscal year 2028 targets and originating more than $1 billion in transactions during the quarter. The stock has delivered a 45.7% return over the past year and trades at $39.68, though InvestingPro analysis suggests it’s slightly overvalued at current levels.
Evercore ISI cuts Carlyle Group stock price target on fee concerns
Investing.com - Evercore ISI lowered its price target on The Carlyle Group () to $42 from $43 while maintaining an In Line rating. The firm reduced its distributable earnings per share estimates for 2027 to $4.85, down 3.1%, and for 2028 to $5.70, down 3.3%, based on lower fee-related performance revenue and transaction fees than previously assumed.
Riverside Resources plans drilling at La Union project in Sonora
VANCOUVER, British Columbia - Riverside Resources Inc. () (OTCQB:RVSDF) (FSE:5YY0) announced that its Phase 2B drilling program at the La Union Project in Sonora, Mexico, is fully funded and expected to begin this month, according to a press release statement. The company plans approximately 600 meters of reverse circulation drilling in two holes of about 300 meters each. Riverside is the operator, with Questcorp Mining Inc. as the option partner under an agreement dated May 6, 2025.
Solventum stock price target raised to $100 by BTIG on results
Investing.com - BTIG raised its price target on Solventum () shares to $100 from $95 while maintaining a Buy rating on Thursday. The company reported third-quarter revenue of $1.949 billion, down 7.0% year-over-year but up 3.5% on an adjusted basis. Adjusted earnings per share came in at $1.45, beating BTIG’s estimate of $1.34 and consensus expectations of $1.34. Revenue fell short of BTIG’s $1.908 billion estimate but exceeded the consensus forecast of $1.931 billion.
Needham raises PAR Technology stock price target on strong Q3 results
Investing.com - Needham raised its price target on PAR Technology () to $30.00 from $25.00 while maintaining a Buy rating on the shares. The new target aligns with the broader analyst consensus, which ranges from $17.50 to $33, according to InvestingPro data. The stock currently trades at $19.18, below InvestingPro’s Fair Value estimate, suggesting potential upside for investors. PAR Technology delivered third-quarter results above the high end of guidance on both revenue and adjusted EBITDA.
Wedbush lowers Vera Therapeutics stock price target on competition
Investing.com - Wedbush lowered its price target on Vera Therapeutics () to $29 from $34 while maintaining a Neutral rating on the stock. The stock currently trades at $30.14, closely aligned with both the new target and InvestingPro’s Fair Value of $29.47. The firm cited the company’s first-quarter launch performance for Trutakna, which generated $10 million in revenue. Vera Therapeutics reported 700 patient start forms since launch but did not disclose the third-quarter 2026 figure.
Needham cuts Axon Enterprise stock price target on revenue guidance
Investing.com - Needham lowered its price target on Axon Enterprise () to $500 from $750 while maintaining a Buy rating on the stock. The stock currently trades at $382.56, down 32% year-to-date and 42% below its 52-week high of $665.07, according to InvestingPro data. Axon reported third-quarter revenue below consensus estimates, though in line with Needham’s projections. The company reduced its total revenue guidance as $130 million in Dedrone revenue is no longer expected.
India draws $1.6 billion in foreign inflows in one day as AI stocks rout
Investing.com - Foreign institutional investors poured a net ~150 billion rupees ($1.6 billion) into Indian equities on Thursday, November 5, the biggest single-day net purchase in nearly six years, as global funds scrambled to exit AI-linked positions in North Asia.
Banc of California declares quarterly dividends on stock
LOS ANGELES - Banc of California, Inc. () announced its Board of Directors declared a quarterly cash dividend of $0.12 per share on outstanding common stock, according to a press release statement. The common stock dividend will be payable on January 4, 2027, to stockholders of record as of December 15, 2026. The Board also declared a quarterly cash dividend of $0.4845 per depositary share on its 7.75% Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series F.
Raymond James raises Royal Gold stock price target on business model strength
Investing.com - Raymond James raised its price target on Royal Gold stock to $337 from $336 while maintaining an Outperform rating. Analyst Brian MacArthur cited the company’s royalty and streaming business model as offering investors exposure to high-margin metal sales that can be increased with minimal general and administrative expenses. The company’s impressive gross profit margin of 87% in the last twelve months underscores this high-margin advantage.
Freedom Broker upgrades American States Water stock rating to buy on higher price target
Investing.com - Freedom Broker upgraded American States Water () to Buy from Hold on Wednesday and raised its price target to $99 from $89. The $3.52 billion water utility currently trades above InvestingPro’s Fair Value estimate, placing it among overvalued stocks in the sector. The firm reported that American States Water posted third-quarter 2026 diluted earnings per share of $1.06, flat year-over-year and 9.6% below the firm’s $1.17 estimate.
Oppenheimer reiterates Kodiak AI stock rating on driverless progress
Investing.com - Oppenheimer reiterated an Outperform rating and $9.00 price target on Kodiak AI () stock. The firm noted that Kodiak AI delivered revenue above expectations as driverless services continue to perform well. The company has made substantial progress on off-the-road autonomy preparation. Oppenheimer said Kodiak AI’s experience producing trucks for off-road deployments should mitigate ramp risk.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Matthew
Contact Matthew, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack